BRD2 and lung cancer: As BRD2 and BRD4 were validated as the upstream regulators of GPX8, inhibition of GPX8 by bromodomain and extra‐terminal (BET) inhibitors may serve as a novel therapeutic potential for lung cancer metastasis.